-Only MCED test on-market to analyze multiple biomarker classes, enhancing early cancer detection

-Offered as a laboratory-developed test at $689

-Nationwide access enabled through Quest Diagnostics’ 7,000 patient access sites

MADISON, Wis., September 10, 2025 — Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) blood test that is now available as a laboratory-developed test (LDT) in the United States. Cancerguard is the first MCED test commercially available that analyzes multiple biomarker classes to help detect a wide range of cancers, including those that often go undiagnosed until later stages when treatment options are limited.

Nearly 70 percent of annual ca

See Full Page